BN Business News
Add your company to Business Communicator →

Regulation & law · 06/11/2018Updated: 10/17/2026 · 1 min read

NHLBI Considers Exclusive Patent License for Insulin Resistance and NASH Treatment

Summary

The National Heart, Lung and Blood Institute is considering granting Ovensa, Inc. an exclusive patent license to commercialize treatments for insulin resistance and non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Original source language: Federal Register — All DocumentsOpen original release →

Explore insights

Business insights →